What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update

Human Pathology

Volumn 38, Issue 1, 2007, Pages 1-16

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinoma; Immunohistochemistry; Mesothelioma

Indexed keywords

CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; ESTROGEN RECEPTOR; KERATIN; KIDNEY ANTIBODY; MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AUA1; MONOCLONAL ANTIBODY BER EP4; MONOCLONAL ANTIBODY BG 8; MONOCLONAL ANTIBODY CA19 9; MONOCLONAL ANTIBODY HEA 125; MONOCLONAL ANTIBODY MOC 31; PODOPLANIN; PROGESTERONE RECEPTOR; PROTEIN P63; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; WT1 PROTEIN;

ADENOCARCINOMA; CARCINOMA; DIFFERENTIAL DIAGNOSIS; EPITHELIOID MESOTHELIOMA; FALSE NEGATIVE RESULT; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MESOTHELIOMA; METASTASIS; OVARY CARCINOMA; PERITONEUM CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SARCOMATOID MESOTHELIOMA; SQUAMOUS CELL CARCINOMA; TUMOR DIAGNOSIS;

CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 33845341114     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.08.010     Document Type: Review

References (157)

1. Chu A.Y., Litzky L.A., Pasha T.L., Acs G., and Zhang P.J. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 18 (2005) 105-110
2. Kimura N., and Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 55 (2005) 83-86
3. Ordóñez N.G. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 36 (2005) 372-380
4. Sienko A., Zander D.S., Killen D., et al. D2-40 is a novel new marker of malignant mesothelioma (MM): tissue microarray study of 45 MM versus 409 lung carcinomas and primary non-mesothelial neoplasms of the pleura and chest wall. Mod Pathol 18 Suppl 1 (2005) 318A [abstract]
5. Ordóñez N.G. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 19 (2006) 34-48
6. Ordóñez N.G. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 19 (2006) 417-428
7. Doglioni C., Dei A., Tos P., et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 20 (1996) 1037-1046
8. Gotzos V., Vogt P., and Celio M.R. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 192 (1996) 137-147
9. Barberis M.C.P., Faleri M., Veronese S., et al. Calretinin: a selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 41 (1997) 1757-1761
10. Leers M.P.G., Aarts M.M.J., and Theunissen P.H.M.H. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 32 (1998) 209-216
11. Ordóñez N.G. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 22 (1998) 1203-1214
12. Ordóñez N.G. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 11 (1998) 929-933
13. Carella R., Deleonardi G., D'Errico A., et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 25 (2001) 43-50
14. Comin C.E., Novelli L., Boddi V., et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 32 (2001) 529-536
15. Abutaily A.S., Addis B.J., and Roche W.R. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 55 (2002) 662-668
16. Attanoos R.L., Webb R., Dojcinov S.D., et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 40 (2002) 237-244
17. Ordóñez N.G. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27 (2003) 1031-1051
18. Ordóñez N.G. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 35 (2004) 697-710
19. Clover J., Oates J., and Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 31 (1997) 140-143
20. Ordóñez N.G. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 22 (1998) 1215-1221
21. Cury P.M., Butcher D.N., Fisher C., et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 13 (2000) 107-112
22. Kaufmann O., Fietze E., Mengs J., and Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116 (2001) 823-830
23. Chu P.G., and Weiss L.M. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 15 (2002) 6-10
24. Amin K.M., Litzky L.A., Smythe W.R., et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146 (1995) 344-356
25. Kumar-Singh S., Segers K., Rodeck U., et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 181 (1997) 67-74
26. Oates J., and Edwards C. HBME-1, MOC-31, WT1 and calretinin: as assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 36 (2000) 341-347
27. Walker C., Rutten F., Yuan X., Pass H., Mew D.M., and Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 54 (1994) 3101-3106
28. Ordóñez N.G. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 24 (2000) 598-606
29. Foster M.R., Johnson J.E., Olson S.J., et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 125 (2001) 1316-1320
30. Miettinen M., Limon J., Niezabitowski A., et al. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 25 (2001) 610-617
31. Collins C.L., Ordóñez N.G., Schaefer R., et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 141 (1992) 827-833
32. Brown R.W., Clark G.M., Tandon A.K., et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 24 (1993) 347-354
33. Attanoos R.L., Goddard H., and Gibbs A.R. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 29 (1996) 209-215
34. Ordóñez N.G. Value of antibodies 44-3A6, SM3, HBME-1 and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 21 (1997) 1399-1408
35. Ordóñez N.G. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology 31 (1997) 25-30
36. Riera J.R., Astengo-Osuna C., Longmate J.A., et al. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 21 (1997) 1409-1419
37. Chenard-Neu M.P., Kabou A., Mechine A., et al. L'immunohistochimie dans le diagnostic différentiel entre mésothéliome et adénocarcinome. Évaluation de 5 nouveaux anticorps et réévaluation de 6 anticorps traditionnels. Ann Pathol 18 (1998) 460-465
38. Chang K., Pai L.H., Pass H., et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16 (1992) 259-268
39. Ordóñez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27 (2003) 1418-1428
40. Ordóñez N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16 (2003) 192-197
41. Wetterwald A., Hofstetter W., Cecchini M.G., et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 18 (1996) 125-132
42. Breiteneder-Geleff S., Matsui K., Soleiman A., et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 151 (1997) 1141-1152
43. Ma T., Yang B., Matthay M.A., et al. Evidence against a role of mouse, rat, and two cloned human t1alpha isoforms as a water channel or a regulator of aquaporin-type water channels. Am J Respir Cell Mol Biol 19 (1998) 143-149
44. Marks A., Sutherland D.R., Bailey D., et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 80 (1999) 569-578
45. Schacht V., Ramirez M.I., Hong Y.-K., et al. T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22 (2003) 3546-3556
46. Schacht V., Dadras S.S., Johnson L.A., et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166 (2005) 913-921
47. Hong Y.K., Harvey N., Noh Y.H., et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 225 (2002) 351-357
48. Sugimoto Y., Watanabe M., Oh-hara T., et al. Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation. Cancer Res 51 (1991) 921-925
49. Watanabe M., Okochi E., Sugimoto Y., et al. Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res 48 (1988) 6411-6416
50. Kato Y., Kaneko M., Sata M., et al. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 26 (2005) 195-200
51. Breiteneder-Geleff S., Soleiman A., Kowalski H., et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154 (1999) 385-394
52. Kahn H.J., Bailey D., and Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 15 (2002) 434-440
53. Ordóñez N.G. Immunohistochemical diagnosis of epithelioid mesothelioma: a critical review of old markers, new markers. Hum Pathol 33 (2002) 953-967
54. Davidson B., Nielsen S., Christensen J., et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25 (2001) 1405-1412
55. Cathro H.P., and Stoler M.H. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 36 (2005) 195-201
56. Martignoni G., Pea M., Chilosi M., et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol 14 (2001) 760-767
57. Osborn M., Pelling N., Walker M.M., Fisher C., and Nicholson A.G. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinoma and mesotheliomas. Histopathology 41 (2002) 301-307
58. Lugli A., Forster Y., Haas P., et al. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol 34 (2003) 994-1000
59. Miettinen M., and Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 27 (2003) 150-158
60. Pritchard S.A., Howat A.J., and Edwards J.M. Immunohistochemical panel for distinction between squamous cell carcinoma, adenocarcinoma and mesothelioma. Histopathology 43 (2003) 197-199
61. Blobel G.A., Moll R., Franke W.W., et al. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 121 (1985) 235-247
62. Goldstein N.S., Bassi D., and Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 116 (2001) 246-252
63. Goldstein N.S., and Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 117 (2002) 541-545
64. Hashi A., Yuminamochi T., Murate S.-I., Iwamoto H., Honda T., and Hoshi K. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 22 (2003) 374-377
65. Al-Hussaini M., Stockman A., Foster H., and McCluggage W.G. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44 (2004) 109-115
66. Muir T.E., Cheville J.C., and Lager D.J. Metanephric adenoma, nephrogenic rests, and Wilms' tumor: a histologic and immunophenotypic comparison. Am J Surg Pathol 25 (2001) 1290-1296
67. Chang K., Pai L.H., Batra J.K., et al. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 52 (1992) 181-186
68. Robinson B.W., Creaney J., Lake R., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362 (2003) 1612-1616
69. Hassan R., Bera T., and Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 10 12 Pt 1 (2004) 3937-3942
70. Ruitenbeek T., Gouw A.S.H., and Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 118 (1994) 265-269
71. Edwards C., and Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed and paraffin wax embedded material. J Clin Pathol 48 (1995) 626-630
72. Sosolik R.C., McGaughy V.R., and De Young B.R. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 10 (1997) 716-719
73. Ordóñez N.G. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 29 (1998) 166-169
74. González-Lois C., Ballentín C., Sotelo M.T., et al. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 38 (2001) 528-534
75. Latza U., Niedobitek G., Schwarting R., et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 43 (1990) 213-219
76. Sheibani K., Shin S.S., Kezirian J., et al. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 15 (1991) 779-784
77. Gaffey M.J., Mills S.E., Swanson P.E., et al. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 16 (1992) 593-599
78. Moch H., Oberholzer H., Dalquen N., et al. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings. Virchows Arch Pathol A Pathol Anat 423 (1993) 19-27
79. Bailey M.E., Brown R.W., Mody D.R., et al. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions: comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Acta Cytol 40 (1996) 1212-1216
80. Ordóñez N.G. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol 109 (1998) 85-89
81. Chenard-Neu M.P., Bellocq J.P., Maier A., et al. Mésothéliomes malins de la plévre. Analyse de leurs aspects immunohistochemiques. Ann Pathol 10 (1990) 20-27
82. Vortmeyer A.O., Preuss J., Padberg B.-C., Kastendieck H., and Schröder S. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas-a clinicomorphological study of 158 cases. Anticancer Res 11 (1991) 889-894
83. Kortsik C.S., Werner P., Freudenberg N., et al. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3-a new tumor marker. Lung 173 (1995) 79-87
84. Hastka J., and Pfiester P. Zellmarker zur Differentiatdiagnose maligner Mesotheliome. Pathologe 9 (1988) 245-247
85. Soosay G.N., Griffiths M., Papadaki L., Happerfield L., and Bobrow L. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J Pathol 163 (1991) 299-305
86. Wang N.S., Huang S.N., and Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma. An immunohistochemical differentiation from other lung cancers. Cancer 44 (1979) 937-943
87. Ordóñez N.G. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 13 (1989) 276-291
88. Wick M.R., Loy T., Mills S.E., et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 21 (1990) 759-766
89. Wirth P.R., Legier J., and Wright Jr. G.L. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 67 (1991) 655-662
90. Roberts F., Harper C.M., Downie I., et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol 116 (2001) 253-262
91. Lafebvre M.P., Rodriguez F., Schlom J., et al. The application of a monoclonal antibody to the differentiation of benign and malignant mesothelial proliferations from adenocarcinomas. Lab Invest 52 (1985) 38A [Abstract]
92. Warnock M.L., Stoloff A., and Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol 133 (1988) 30-38
93. Garcia-Prats M.D., Ballestin C., Sotelo T., et al. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology 32 (1998) 462-472
94. y, in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 135 (1989) 931-937
95. Sheibani K., Battifora H., and Burke J.S. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 123 (1986) 212-219
96. Wick M.R., Swanson P.E., and Manivel J.C. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum Pathol 18 (1987) 946-954
97. Bollinger D.J., Wick M.R., Dehner L.P., Mills S.E., Swanson P.E., and Clarke R.E. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma: a histochemical and immunohistochemical comparison. Am J Surg Pathol 13 (1989) 659-670
98. Wick M.R., Mills S.E., Dehner L.P., Bollinger D.J., and Fechner R.E. Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol 8 (1989) 179-188
99. Khoury N., Raju U., Crissman J.D., Zarbo R.J., and Greenawald K.A. A comparative immunohistochemical study of peritoneal and ovarian serous tumors and mesotheliomas. Hum Pathol 21 (1990) 811-819
100. Truong L.D., Maccato M.L., Awalt H., Cagle P.T., Schwartz M.R., and Kaplan A.L. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol 21 (1990) 99-110
101. Zhou J., Iwasa Y., Konishi I., et al. Papillary serous carcinoma of the peritoneum in women: a clinicopathologic and immunohistochemical study. Cancer 76 (1995) 429-436
102. Gibbs A.R., Harach R., Wagner J.C., et al. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 40 (1985) 91-95
103. Pfaltz M., Odermatt B., Christen B., and Rüttner J.R. Immunohistochemistry in the diagnosis of malignant mesothelioma. Virchows Arch A 411 (1987) 387-393
104. Winter M.J., Nagtegaal I.D., van Krieken J.H.J.M., and Litvinov S.V. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163 (2003) 2139-2148
105. Linnenbach A.J., Seng B.A., Wu S., et al. Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol 13 (1993) 1507-1515
106. Litvinov S.V., Velders M.P., Bakker H.A.M., Fleuren G.J., and Warnaar S.O. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125 (1994) 437-446
107. De Leij L., Poppema S., Klein Nulend J.K., Ter Haar J.G., Schwander E., and The T.H. Immunoperoxidase staining on frozen tissue sections as a first screening assay in the preparation of monoclonal antibodies directed against small cell carcinoma of the lung. Eur J Cancer Clin Oncol 20 (1984) 123-128
108. Ascoli V., Scalzo C.C., Taccogna S., et al. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med 119 (1995) 1136-1140
109. Shield P.W., Callan J.J., and Devine P.L. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 11 (1994) 237-245
110. Moldenhauer G., Momburg F., Moller P., Schwartz R., and Hammerling G.J. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 56 (1987) 714-721
111. r 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. J Cancer Res 47 (1987) 2883-2891
112. Spurr N.K., Durbin H., Sheer D., Parkar M., Bobrow L., and Bodmer W.F. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUA1. Int J Cancer 38 (1986) 631-636
113. Johnston W.W. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. Acta Cytol 31 (1987) 537-556
114. Loy T.S., and Nashelsky M.B. Reactivity of B72.3 with adenocarcinomas: an immunohistochemical study of 476 cases. Cancer 72 (1993) 2495-2498
115. Lyda M.H., and Weiss L.M. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 31 (2000) 980-987
116. López-Ferrer A., Barranco C., and de Bolós C. Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma. Am J Clin Pathol 118 (2002) 749-755
117. Magnani J.L., Steplewski Z., Koprowski H., and Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43 (1983) 5489-5492
118. Ordóñez N.G., Freedman R.S., and Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol 26 (1987) 1-10
119. Khoor A., Whitsett J.A., Stahlman M.T., et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 30 (1999) 695-700
120. Ordóñez N.G. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol 7 (2000) 123-127
121. Noguchi M., Nakajima T., Hirohashi S., et al. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewis, and anti-Tn antibodies. Hum Pathol 20 (1989) 53-57
122. Kaufmann O., and Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 36 (2000) 8-16
123. Pan C.C., Chen P.C., Chou T.Y., and Chiang H. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol 34 (2003) 1155-1162
124. Yoshida S.O., and Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res 49 (1989) 1802-1809
125. Avery A.K., Beckstead J., Renshaw A.A., and Corless C.L. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 24 (2000) 203-210
126. McGregor D.K., Khurana K.K., Cao C., et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'renal cell carcinoma marker'. Am J Surg Pathol 25 (2001) 1485-1492
127. Trupiano J.K., Geisinger K.R., Willingham M.C., et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 17 (2004) 476-481
128. Ordóñez N.G. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol 36 (2005) 1163-1167
129. Barnetson R.J., Burnett R.A., Downie I., Harper C.M., and Roberts F. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum. Antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 125 (2006) 67-76
130. Peralta-Soler A., Knudsen K.A., Jaurand M.C., et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 26 (1995) 1363-1369
131. Ordóñez N.G. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. Hum Pathol 34 (2003) 749-755
132. Han A.C., Peralta-Soler A., Knudsen K.A., et al. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol 28 (1997) 641-645
133. Miettinen M., and Kovatich A.J. HBME-1-a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumors. Appl Immunohistochem 3 (1995) 115-122
134. Bateman A.C., Al-Talib R.K., Newman T., et al. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 30 (1997) 49-56
135. Attanoos R.L., Webb R., and Gibbs A.R. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology 30 (1997) 260-263
136. Afify A.M., Stern R., Jobes G.A., et al. Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias. Applied Immunohistochem 6 (1998) 11-15
137. Filie A.C., Abati A., Fetsch P., et al. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: disappointing results in cytology material. Diagn Cytopathol 18 (1998) 473-474 [letter]
138. Fujimoto I., Hirai Y., Hasumi K., Masubuchi K., and Osamura Y. The value of epithelial membrane antigen in the diagnosis of ovarian tumors. Acta Cytol 34 (1990) 549-554
139. Leong A.S.-Y., Parkinson R., and Milios J. "Thick" cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma. Diagn Cytopathol 6 (1990) 9-13
140. Marshall R.J., Herbert A., Braye S.G., and Jones D.B. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium. J Clin Pathol 37 (1984) 1215-1221
141. Battifora H., and Kopinski M.I. Distinction of mesothelioma from adenocarcinoma: an immunohistochemical approach. Cancer 55 (1985) 1679-1685
142. Delahaye M., Hoogsteden H.C., and van der Kwast T.H. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 165 (1991) 137-143
143. Abati A., and Fetsch P.A. OV632 as a possible marker for malignant mesothelioma: high expectations; low specificity. Diagn Cytopathol 12 (1995) 81-82
144. Lee I., Radosevich J.A., Chejfec G., et al. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Am J Pathol 123 (1986) 497-507
145. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 9 (1985) 360-365
146. Brockstedt U., Gulyas M., Dobra K., et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 114 (2000) 203-209
147. Mayall F.G., Goddard H., and Gibbs A.R. Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon. Histopathology 21 (1992) 453-457
148. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 25 (1994) 753-757
149. Afify A.M., Al-Khafaji B.M., Paulino A.F.G., and Davila R.M. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol 10 (2002) 178-182
150. Kondi-Paphitis A., and Addis B.J. Secretory component in pulmonary adenocarcinoma and mesothelioma. Histopathology 10 (1986) 1279-1287
151. Ramussen O.O., and Larsen K.E. S-100 protein in malignant mesotheliomas. Acta Pathol Microbiol Immunol Scand (A) 93 (1985) 199-201
152. Chang Y.-L., Lee Y.-C., Liao W.-Y., and Wu C.-T. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 44 (2004) 149-157
153. Nakamura N., Miyagi E., Murata S., Kawaoi A., and Katoh R. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol 15 (2002) 1058-1067
154. Yang A., Kaghad M., Wang Y., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2 (1998) 305-316
155. Au N.H.C., Gown A.M., Cheang M., et al. p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12 (2004) 240-247
156. Reis-Filho J.S., Simpson P.T., Martins A., Preto A., Gartner F., and Schmitt F.C. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 443 (2003) 122-132
157. Zhang H., Liu J., Cagle P.T., Allen T.C., Laga A.C., and Zander D.S. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol 18 (2005) 111-118